Research Articles
Unlocking the Immune System: The Pyrazole Breakthrough in Cancer Treatment
Discover how pyrazole molecules are revolutionizing cancer immunotherapy by inhibiting HPK1, the immune system's hidden brake mechanism.
Cherry-Red Plasma: Unraveling the Impact of a Cancer Drug on Lab Tests
Exploring how PV-10 cancer immunotherapy causes cherry-red plasma and interferes with laboratory tests while activating anti-tumor immunity.
Personalized Cancer Nanovaccines: A Revolutionary Precision Approach to Immunotherapy
Explore the science behind personalized peptide-based cancer nanovaccines - a groundbreaking immunotherapy approach that trains the immune system to target cancer cells with precision.
Breaking the "Undruggable" Barrier: How MYC Inhibitors Are Revolutionizing Cancer Immunotherapy
Discover how small molecule MYC inhibitors are overcoming historical challenges and enhancing cancer immunotherapy through innovative approaches.
Nanovaccines: Training Your Immune System to Fight Cancer with Nanotechnology
Explore how nanotechnology is revolutionizing cancer immunotherapy through nanovaccines that train the immune system to fight cancer cells with precision.
Cracking Cancer's Defense Code: How AI is Powering the Next Generation of Cancer Immunotherapy
Discover how graph neural networks and molecular docking are revolutionizing cancer immunotherapy by identifying potent PD-1/PD-L1 small molecule inhibitors.
Re-educating the Guardians: How a Novel CSF1R Inhibitor Transforms Tumor-Associated Macrophages to Combat Cancer
Discover how FF-10101, a novel CSF1R inhibitor with unique covalent binding, reprograms tumor-associated macrophages to create an anti-tumor immune environment and enhances cancer immunotherapy.
Bullseye on Cancer Cells: The Revolutionary Antibody Guiding Therapy to Tumors
Explore the groundbreaking Phase I trial of hu3S193, a humanized monoclonal antibody targeting Lewis-Y antigen in epithelial cancers. Learn about its precision targeting, pharmacokinetics, and future therapeutic potential.